Overexpression of Tissue VEGF-A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer

PURPOSE: This phase II trial evaluated bevacizumab plus erlotinib in platinum-resistant ovarian cancer; exploratory biomarker analyses, including that of tumor vascular endothelial growth factor (VEGF-A), were also performed. EXPERIMENTAL DESIGN: Forty heavily pretreated patients received erlotinib...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Chambers, Setsuko K., Clouser, Mary C., Baker, Amanda F., Roe, Denise J., Cui, Haiyan, Brewer, Molly A., Hatch, Kenneth D., Gordon, Michael S., Janicek, Mike F., Isaacs, Jeffrey D., Gordon, Alan N., Nagle, Raymond B., Wright, Heather M., Cohen, Janice L., Alberts, David S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3074583/
https://ncbi.nlm.nih.gov/pubmed/21041183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0974
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi